» Articles » PMID: 22104008

Evaluation of Molecular Modeling of Agonist Binding in Light of the Crystallographic Structure of an Agonist-bound A₂A Adenosine Receptor

Overview
Journal J Med Chem
Specialty Chemistry
Date 2011 Nov 23
PMID 22104008
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Molecular modeling of agonist binding to the human A(2A) adenosine receptor (AR) was assessed and extended in light of crystallographic structures. Heterocyclic adenine nitrogens of cocrystallized agonist overlaid corresponding positions of the heterocyclic base of a bound triazolotriazine antagonist, and ribose moiety was coordinated in a hydrophilic region, as previously predicted based on modeling using the inactive receptor. Automatic agonist docking of 20 known potent nucleoside agonists to agonist-bound A(2A)AR crystallographic structures predicted new stabilizing protein interactions to provide a structural basis for previous empirical structure activity relationships consistent with previous mutagenesis results. We predicted binding of novel C2 terminal amino acid conjugates of A(2A)AR agonist CGS21680 and used these models to interpret effects on binding affinity of newly synthesized agonists. d-Amino acid conjugates were generally more potent than l-stereoisomers and free terminal carboxylates more potent than corresponding methyl esters. Amino acid moieties were coordinated close to extracellular loops 2 and 3. Thus, molecular modeling is useful in probing ligand recognition and rational design of GPCR-targeting compounds with specific pharmacological profiles.

Citing Articles

Identification of Novel Chemical Entities for Adenosine Receptor Type 2A Using Molecular Modeling Approaches.

Santos K, Cruz J, Silva L, Ramos R, Neto M, Lobato C Molecules. 2020; 25(5).

PMID: 32164183 PMC: 7179438. DOI: 10.3390/molecules25051245.


Accelerating the Throughput of Affinity Mass Spectrometry-Based Ligand Screening toward a G Protein-Coupled Receptor.

Lu Y, Qin S, Zhang B, Dai A, Cai X, Ma M Anal Chem. 2019; 91(13):8162-8169.

PMID: 31094506 PMC: 6669887. DOI: 10.1021/acs.analchem.9b00477.


Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design.

Ciancetta A, Jacobson K Methods Mol Biol. 2017; 1705:45-72.

PMID: 29188558 PMC: 5859332. DOI: 10.1007/978-1-4939-7465-8_3.


Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics.

Hothersall J, Guo D, Sarda S, Sheppard R, Chen H, Keur W Mol Pharmacol. 2016; 91(1):25-38.

PMID: 27803241 PMC: 5198511. DOI: 10.1124/mol.116.105551.


The discovery of a selective and potent A2a agonist with extended lung retention.

Astrand A, Lamm Bergstrom E, Zhang H, Borjesson L, Soderdahl T, Wingren C Pharmacol Res Perspect. 2015; 3(3):e00134.

PMID: 26236482 PMC: 4492750. DOI: 10.1002/prp2.134.


References
1.
Katritch V, Abagyan R . GPCR agonist binding revealed by modeling and crystallography. Trends Pharmacol Sci. 2011; 32(11):637-43. PMC: 3200445. DOI: 10.1016/j.tips.2011.08.001. View

2.
Kim J, Wess J, Van Rhee A, Schoneberg T, Jacobson K . Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. J Biol Chem. 1995; 270(23):13987-97. PMC: 3427751. DOI: 10.1074/jbc.270.23.13987. View

3.
Wu B, Chien E, Mol C, Fenalti G, Liu W, Katritch V . Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science. 2010; 330(6007):1066-71. PMC: 3074590. DOI: 10.1126/science.1194396. View

4.
Tyndall J, Sandilya R . GPCR agonists and antagonists in the clinic. Med Chem. 2006; 1(4):405-21. DOI: 10.2174/1573406054368675. View

5.
Kellenberger E, Rodrigo J, Muller P, Rognan D . Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins. 2004; 57(2):225-42. DOI: 10.1002/prot.20149. View